Previous Close | 2.8500 |
Open | 2.7300 |
Bid | 2.7500 x N/A |
Ask | 2.7900 x N/A |
Day's Range | 2.6000 - 2.8000 |
52 Week Range | 0.6750 - 3.0505 |
Volume | |
Avg. Volume | 470,154 |
Market Cap | 725.841M |
Beta (5Y Monthly) | 1.32 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.34 |
Subscribe to Yahoo Finance Plus to view Fair Value for CU6.AX
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the successful completion of cohort 3 and advancement to cohort 4, the first multi-dose cohort in the SECuRE trial.
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA (NCT05249127)[1].
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE.